On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression.
Med (New York, N.Y.) January 13, 2023 DOI: 10.1016/j.medj.2022.12.003 via PubMed
Summary
AI-generated from the abstractA Phase II trial of psilocybin-assisted therapy for treatment-resistant depression showed modest effectiveness but also raised concerns about serious adverse effects. The findings underscore the importance of carefully evaluating whether blinding in such trials is maintained, accounting for participant expectations, and investigating factors that may increase risk in vulnerable groups.
Study at a glance
| Characteristics | Phase II trial Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Intervention | Psilocybin-assisted therapy |
| Topics | Psychedelic-assisted therapy |
| Keywords | Mental health treatment Depression research Clinical trials Drug safety |
| Citations | 12 |
| Key finding | Psilocybin-assisted therapy showed modest efficacy for treatment-resistant depression but raised concerns about serious adverse effects. |
Abstract
Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression1 suggest modest efficacy but raise concerns about potential for serious adverse effects. The study highlights the need for rigorous assessment of blinding integrity, expectancy, and further study of factors that may contribute to risk in vulnerable populations.